In Wednesday’s trading session, Applied DNA Sciences Inc. (NASDAQ: APDN) gained 13.20%, which is $0.96 higher than the previous market close price. In the trading session, the lowest point for the Applied DNA stock was $7.90, while the highest price was recorded at a share price of $9.96.
In the previous session, APDN stock closed at $7.27, according to Barchart, while $9.32 million worth of shares were traded. The APDN stock soared after Applied DNA signed a collaboration agreement for COVID-based research.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
What was the collaboration?
Its proprietary, large-scale PCR-based manufacturing platform will allow Applied DNA to manufacture specific DNA sequences on a large scale, enabling the commercialization of LinearDNA. The LinearDNA platform has application in the diagnostics market of nucleic acid-based products, and the process of developing and manufacturing nucleic acid-based drugs.
Applied DNA and Northwell Health entered into a pro bono Material Transfer Agreement (MTA), as announced APDN yesterday.
- Northwell’s CoVID-positive specimens can now be tracked in real-time using a real-time surveillance program established by the MTA for tracking and identification of variants of concern in SARS-CoV-2.
- As of right now, two thousand samples have been analyzed for the program, while preliminary results indicate that approximately 80% of specimens tested on the Company’s qPCR assays contain a mutation.
- In the future, utilizing data generated from the Program will enable Northwell to employ less costly and time-consuming next-generation sequencing (NGS) in order to definitively identify specific VOCs and subsequent descendants.
Finally,
A white paper (APDN-authored) on detecting the presence of SARS-CoV-2 will be published soon. Both parties will be able to monetize aggregate data from the Program under a revenue-share arrangement.
